COMPLETED

A Study to Evaluate the Performance, Usability, and Result Interpretation of INSTI® HIV Self-Test

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The objective of this study is to evaluate the performance, usability, and result interpretation of the INSTI® HIV Self-Test (referred to INSTI® HIV ST) in the intended use population across the United States (US). The INSTI® HIV Self-Test is a single use in vitro test that is used as a self-test for the detection of antibodies to HIV-1 and HIV-2 in human fingerstick blood. This study is designed to evaluate INSTI® HIV ST performance in the hands of non-professionals and untrained lay users who are inexperienced in HIV blood-based self-testing. The study aims to: To evaluate the clinical performance (i.e., diagnostic sensitivity and specificity) of the INSTI® HIV Self-Test in a lay user population. To assess the user's comprehension of the INSTI® HIV ST results (e.g., interpreting positive, negative, and invalid results). To evaluate the usability of the INSTI® HIV ST and understand users' experience in performing the test.

Official Title

A Study to Evaluate the Performance, Usability, and Result Interpretation of INSTI® HIV Self-Test When Performed by Observed Intended Users in the US

Quick Facts

Study Start:2024-05-02
Study Completion:2025-01-08
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT06368453

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * 18 years of age or older
  2. * Operator/study staff must complete the subject's Enrolment Questionnaire
  3. * Subject to sign and date the Informed Consent Form
  4. * Able to complete the required testing on the allocated testing day(s).
  5. * Able to speak/ read/write English or Spanish
  6. * Willingness to provide the fingerstick blood sample and if necessary, the volume of whole blood collected through venous blood draw (approximately 7 ml)
  7. * Willingness to participate in the study site's standard of care HIV counselling and testing program and receive the study site's standard of care test results
  8. * Unknown HIV Status
  1. * Has participated in any prior, or concurrent trial of HIV self-tests
  2. * Is a practicing medical healthcare professional (doctor, nurse or HIV Counsellor that performs HIV testing with Rapid Tests)
  3. * Is currently on a PrEP regimen
  4. * Has used a Rapid Diagnostic Test for HIV blood-based self-testing previously
  5. * Has received any experimental HIV vaccine
  6. * Has a bleeding disorder
  7. * Is known HIV+
  8. * Uses Anti-Retroviral medication
  9. * Any condition which, in the opinion of the Operator, would make the participant unsuitable or unsafe for enrolment or could interfere with the completion of the assessment, consent form and questionnaire etc. or bias the outcome, i.e., being unable to see / read by forgetting to bring reading glasses, being intoxicated or acute sickness, or visibly distressed.

Contacts and Locations

Principal Investigator

Steven A Geller
PRINCIPAL_INVESTIGATOR
Centennial Medical Group
Anthony LaMarca
PRINCIPAL_INVESTIGATOR
Therafirst Medical Centers Inc.

Study Locations (Sites)

Therafirst Medical Center
Fort Lauderdale, Florida, 33308
United States

Collaborators and Investigators

Sponsor: bioLytical Laboratories

  • Steven A Geller, PRINCIPAL_INVESTIGATOR, Centennial Medical Group
  • Anthony LaMarca, PRINCIPAL_INVESTIGATOR, Therafirst Medical Centers Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-05-02
Study Completion Date2025-01-08

Study Record Updates

Study Start Date2024-05-02
Study Completion Date2025-01-08

Terms related to this study

Keywords Provided by Researchers

  • HIV Self Test
  • INSTI HIV Self test
  • HIV-1/2 Antibody Test
  • In-Home HIV test

Additional Relevant MeSH Terms

  • Human Immunodeficiency Virus I Infection
  • Human Immunodeficiency Virus II Infection